Bionano: AMA establishes new category I CPT code for OGM in malignacy analysis

Bionano Laboratories, a clinical laboratory services business of Bionano Genomics, announced the editorial panel of the American Medical Association, AMA, established a new Category I Current Procedural Terminology CPT code for the use of optical genome mapping ,OGM, in cytogenomic genome-wide analysis to detect structural and copy number variations related to hematological malignancies. The CPT code is a key component in obtaining reimbursement for the OGM-Dx(TM) HemeOne laboratory developed test, LDT, from third party payers. The Category I CPT code is expected to be included in the next CPT codebook and to be effective January 1. The establishment of a new Category I CPT code for OGM implies that it has met the standards of acceptance by the medical community, in contrast to a Category III code, which is generally applied to emerging technologies. As part of the application review process, the panel collects input from stakeholders across the health care community to ensure CPT content reflects the coding and data-driven demands of modern health care.